Zlotta AR - Search Results

1

What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC. Zlotta AR, et al. Eur Urol. 2000 Apr;37(4):470-7. doi: 10.1159/000020170. Eur Urol. 2000. PMID: 10765079 Clinical Trial.

2

Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.

Zlotta A, Drowart A, van Vooren JP, Simon J, Schulman CC, Huygen K. Zlotta A, et al. Acta Urol Belg. 1994 Sep;62(3):63-8. Acta Urol Belg. 1994. PMID: 7976857

3

Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience.

Schulman CC, Zlotta AR. Schulman CC, et al. Among authors: zlotta ar. Urology. 1995 Jan;45(1):28-33. doi: 10.1016/s0090-4295(95)96260-3. Urology. 1995. PMID: 7529447 Clinical Trial.

4

Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia.

Zlotta AR, Raviv G, Schulman CC. Zlotta AR, et al. Eur Urol. 1996;30(2):249-55. doi: 10.1159/000474176. Eur Urol. 1996. PMID: 8875207 Review.

5

Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.

Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K. Zlotta AR, et al. J Urol. 1997 Feb;157(2):492-8. J Urol. 1997. PMID: 8996341

6

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.

Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Mascart F, Simon J, Schulman CC, Van Vooren JP. Zlotta AR, et al. Clin Exp Immunol. 1997 Jul;109(1):157-65. doi: 10.1046/j.1365-2249.1997.4141313.x. Clin Exp Immunol. 1997. PMID: 9218839 Free PMC article.

7

Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions.

Schulman CC, Wildschutz T, Zlotta AR. Schulman CC, et al. Among authors: zlotta ar. Eur Urol. 1997;32 Suppl 3:41-7. Eur Urol. 1997. PMID: 9267784 Review.

8

Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.

Zlotta AR, Drowart A, Van Vooren JP, Shekarsarai H, De Cock M, Pirson M, Palfliet K, Jurion F, Simon J, Schulman CC, Huygen K. Zlotta AR, et al. J Urol. 1998 Jun;159(6):1885-91. doi: 10.1016/S0022-5347(01)63186-0. J Urol. 1998. PMID: 9598481

9

Etiology and diagnosis of prostate cancer: what's new? A review.

Zlotta AR, Schulman CC. Zlotta AR, et al. Eur Urol. 1998;33(4):351-8. doi: 10.1159/000019615. Eur Urol. 1998. PMID: 9612676 Review. No abstract available.

10

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC. Zlotta AR, et al. J Urol. 1999 Mar;161(3):792-8. J Urol. 1999. PMID: 10022686

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

280 results

Search Page

Filters